论文部分内容阅读
采用一步法竞争原理,用放射免疫分析法对149例各种晚期恶性肿瘤病人的血清白细胞介素2(Interleukin,IL-2)水平进行检测。结果显示,各晚期恶性肿瘤组血清IL-2水平均显著低于正常对照组(p<0.001),且这种低水平血清IL-2浓度的患者愈后极差,平均生存期为24.5±18d,有16例血清IL-2水平<1.5ng/ml者,在3.8±1.8d内死亡。提示,血清IL-2水平测定适用于各种晚期恶性肿瘤病人病情监测及对预后的判断。
Using a one-step competition principle, serum interleukin 2 (IL-2) levels in 149 patients with various advanced cancers were measured by radioimmunoassay. The results showed that the levels of serum IL-2 in advanced malignant tumors were significantly lower than those in normal controls (p<0.001). The patients with low serum IL-2 concentrations were extremely poor with an average survival of 24.5±18 days. There were 16 patients with serum IL-2 levels <1.5ng/ml who died within 3.8±1.8d. It is suggested that the determination of serum IL-2 level is suitable for monitoring the condition of patients with various advanced malignant tumors and judging the prognosis.